REQUEST A DEMO
Total
USD $0.00
Search more companies

Zdravlje A.D. Leskovac (Serbia)

Main Activities: Pharmaceutical Preparation Manufacturing
Full name: Zdravlje A.D. Leskovac Profile Updated: June 12, 2024
Buy our report for this company USD 29.95 Most recent financial data: 2023 Available in: English Download a sample report

Serbian drug maker FHI Zdravlje, which was founded in 1953, is one of the largest players on the country's pharmaceutical market. The pharmaceuticals factory, which is located in Leskovac, manufactures medicines, medical solutions and creams.
Icelandic generic drug maker Actavis, former Pharmaco, bought in late 2002 a 70% stake in Zdravlje for EUR 3.5 million and pledged to invest EUR 20-25 million over the next five years.

Headquarters
Vlajkova 199
Leskovac; Jablanica; Postal Code: 16000

Contact Details: Purchase the Zdravlje A.D. Leskovac report to view the information.

Website: http://www.actavis.rs

Basic Information
Total Employees:
Purchase the Zdravlje A.D. Leskovac report to view the information.
Outstanding Shares:
Purchase the Zdravlje A.D. Leskovac report to view the information.
Registered Capital:
Purchase the Zdravlje A.D. Leskovac report to view the information.
Financial Auditors:
Purchase the Zdravlje A.D. Leskovac report to view the information.
Incorporation Date:
December 25, 1953
Key Executives
Purchase this report to view the information.
Chairman of the Board of Directors
Purchase this report to view the information.
Member of the Board of Directors
Purchase this report to view the information.
Member of the Board of Directors
Purchase this report to view the information.
Procurator
Purchase this report to view the information.
Procurator
Ownership Details
Purchase this report to view the information.
100%
Subsidiaries
Frontier Biopharma
100%
Company Performance
Financial values in the chart are available after Zdravlje A.D. Leskovac report is purchased.
Looking for more than just a company report?

EMIS company profiles are part of a larger information service which combines company, industry and country data and analysis for over 145 emerging markets.

Request a demo of the EMIS service
Key Financial Highlights
Annual growth percentages for latest two years in local currency RSD. Absolute financial data is included in the purchased report.
Net sales revenue
22.15%
Total operating revenue
21.92%
Operating profit (EBIT)
89.49%
EBITDA
1608.7%
Net Profit (Loss) for the Period
44.21%
Total assets
-9.09%
Total equity
-7.13%
Operating Profit Margin (ROS)
9.3%
Net Profit Margin
5.43%
Return on Equity (ROE)
5.09%
Debt to Equity Ratio
-6.24%
Quick Ratio
-0.15%
Cash Ratio
0.04%

To view more information, Request a demonstration of the EMIS service

Buy this company report
Need ongoing access to company, industry or country information?